Trial
NCT04703426
Sargramostim (GM-CSF) + PD-1
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Partner Therapeutics (PTx)
Condition
Unresectable Melanoma
Intervention
Sargramostim (GM-CSF)
Why stopped
Study terminated by sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-22